Endothelial hyperpermeability is involved in several critical illnesses, and its regulatory mechanisms have been intensively investigated. It was recently reported that the activation peptide of coagulation factor IX enhances cell matrix and intercellular adhesion. The aim of this study was to investigate the role of activation peptide of coagulation factor IX in intercellular adhesion of endothelial cells and evaluate its effects on endothelial permeability. In the presence of activation peptide, cells spread with lamellipodium-like broad protrusions multidirectionally, increasing the area of adhesion to matrix by 16% within 30 minutes. In intercellular adhesion, treatment with activation peptide induced overlapping of adjacent cell edges and remodeling of intercellular adhesion sites, with colocalization of the adherens junction proteins VE-cadherin and bcatenin and a marker protein of the lateral border recycling compartment, PE-CAM. Activation peptide decreased gaps between cells by 66% in cultured endothelial cells and suppressed increased endothelial cell monolayer permeability induced by interleukin-1b in a dose-dependent manner. Treatment with activation peptide decreased eNOS protein expression and altered its subcellular distribution, decreasing intracellular cGMP. An analogue of cGMP suppressed the effects of activation peptide on cell spreading. In addition, the effect of activation peptide on hyperpermeability was investigated in mice injected with lipopolysaccharide. Intravenous injection of lipopolysaccharide increased lung weight by 28%, and treatment with activation peptide significantly suppressed the increase in lung weight to 5%. Our results indicate that activation peptide of factor IX regulates endothelial intercellular adhesion and thus could be used in the treatment of vascular hyperpermeability. (Translational Research 2016;177:70-84) Abbreviations: FIX ¼ coagulation factor IX; PECAM ¼ platelet endothelial cell adhesion mole-
INTRODUCTION
Vascular permeability is strictly regulated to reconcile 2 conflicting aims: selective molecular transport and the barrier function between blood and tissues. Tissues must receive nourishment and oxygen from the blood and excrete waste products to the blood. Endothelial cells play a major role in regulating vascular permeability under the influence of numerous factors. There are 2 routes of fluid extravasation: transcellular transport, by which fluids pass through endothelial cells by vesicular trafficking; and paracellular transport, involving modulation of intercellular adhesion. 1 Transcellular transport occurs through caveolae, vesiculovacuola organelles, and transcellular channels. 2, 3 Caveolae are 'dents' in the plasma membrane containing caveolin-1 and are the sites of caveolindependent endocytosis. Caveolin-1 is a protein important in transcellular transport, and its expression can be suppressed by targeting the caveolin-1 gene. 4, 5 Paracellular transport is regulated by barrier stability, which is maintained by anchorage of adherens and tight junctions to the actin cytoskeleton. 6 Adherens junctions are formed with calcium-dependent VE-cadherin protein. Paracellular transport is stimulated by a number of humoral factors, including VEGF, histamine, thrombin, and bradykinin, which induce phosphorylation of specific tyrosine residues (Y658 and Y731) of VE-cadherin. 7, 8 Phosphorylation of VE-cadherin results in internalization of the protein and attenuation of intercellular adhesion, increasing paracellular perme-ability. Intracellularly, VEGF, bradykinin, and prostaglandin E2 control endothelial permeability through the production of nitric oxide (NO). [9] [10] [11] [12] [13] Increased endothelial permeability has important implications in the pathophysiology and prognosis of many diseases. The permeability of the vascular endothelium is one of the factors that determine the fluid balance in organs and tissues. Vascular permeability must be precisely controlled for normal organ and tissue function, particularly in the lungs. To maintain the efficiency of gas exchange, the lungs constantly maintain an optimal amount of fluid. Dysregulation of the fluid balance in the lungs can result in hypoxia, which can be life-threatening. In addition, immune reactions arising in response to infection or allergies enhance endothelial permeability. In these cases, humoral factors such as interleukin (IL), bradykinin, and histamine and pathogen-derived lipopolysaccharide (LPS) increase vascular permeability. 2, 9, 14, 15 In addition, hypoxia increases the expression of VEGF, which is a potent endothelial permeability-enhancing factor. Moreover, the tissue damage resulting from ischemia can trigger an inflammatory reaction. 16, 17 Coagulation reactions can also enhance endothelial permeability. In addition, various factors involved in hemostasis have been found to increase permeability, including thrombin and platelet-activating factors. Thrombus-associated angiopathy causes ischemia, thus increasing permeability. The inter-related nature of infection, inflammation, coagulation, and ischemia in diseases such as sepsis, disseminated intravascular coagulation (DIC), and acute respiratory distress syndrome indicates that numerous factors may increase endothelial permeability in a cooperative manner.
The number of reports regarding factors that suppress increases in permeability and maintain endothelial barrier functions continues to increase because it is thought that such factors would be effective in treating diseases such as sepsis, DIC, and acute respiratory distress syndrome. Humoral factors, catecholamines, thrombomodulin, activated protein C (APC), and prostaglandins are known to enhance endothelial barrier functions. For example, the injection of adrenalin is an effective treatment for increased lung permeability. 18 Thrombomodulin is reportedly effective in the treatment of DIC due to its anticoagulation activity and involvement in protection of the endothelial barrier. 19, 20 The results of sepsis model studies suggest that APC and sphingosine-1-phosphate (S1P) would be effective treatments for barrier dysfunction. 21, 22 Coagulation factor IX (FIX) is an essential molecule for normal coagulation. Mutations in FIX lead to hemophilia B, which results in abnormal bleeding. In the coagulation process, FIX is cleaved at Arg192 and AT A GLANCE COMMENTARY Mamiya A, et al.
Background
Sepsis with systemic inflammatory response syndrome is a life-threatening disease even in developed countries. Currently, there are not any established therapeutic methods for the clinical condition. The activation peptide of coagulation factor IX has been considered as a blocking peptide of its catalytic activity in coagulation.
Translational Significance
In this study, we show that the activation peptide strengthens barrier function of endothelial cells in vitro and in vivo. Lung edema in sepsis model was suppressed by the peptide. This study suggests that the activation peptide could be a potential therapeutic agent for sepsis with systemic inflammatory response syndrome.
Arg236 by activated factor XI or the factor VIIa/TF complex, releasing an activation peptide from FIX and resulting in the activation of FIX. 23 Kitano et al. 24 reported that activated FIX increases the rate of cell migration, weakens adhesion to matrix, and weakens intercellular adhesion. In contrast, native FIX and the activation peptide suppress migration, increase adhesion to matrix, and enhance intercellular adhesion. Moreover, the activation peptide suppresses the effects of activated FIX. Because diseases involving abnormally high-endothelial permeability are related to coagulation, it is thought that activated FIX could be involved in increasing endothelial permeability. Our hypothesis is that the activation peptide could be an effective treatment due to its involvement in maintaining endothelial barrier functions. Therefore, in the present study, we examined the effects of the FIX activation peptide on endothelial permeability both in vitro and in vivo. Reagents. We generated several FIX deletion mutants by RT-PCR and cloned them into an alkaline phosphatase (AP)-tag4 vector (GenHunter, Nashville, Tenn) for production of AP-tagged FIX as a secreted protein in CHO cells cultured in 64 medium. 25, 26 The DNA constructs included mouse full-length FIX (amino acids 47-471; accession number AK149372) without the amino-terminal propeptide, a fragment of FIX lacking the heavy chain (amino acids 47-236), the FIX light chain (amino acids , the activation peptide (amino acids 193-236), and the first EGF domain of FIX (amino acids 97-130). Chemically synthesized peptides (FIX amino acids 193-216 and 193-210) and a control peptide were purchased from Operon Technology (Tokyo, Japan). To optimize the peptide synthesis conditions, poly K was added to the C terminus of synthesized peptides as AETVFSMDYENSTEAVFIQDDITKKKKKK.
EXPERIMENTAL PROCEDURES
The control peptide consisted of amino acids 193-216 in reverse sequence with a poly K tail. Antibodies recognizing eNOS, integrin b1, and caveolin-1 were purchased from Abcam (Cambridge, Mass). Antibodies recognizing VE-cadherin and E-cadherin were purchased from Cell Signaling Technology (Beverly, Mass) and Takara (Ohtsu, Japan),
respectively. An antibody specific for b-catenin was purchased from Becton Dickinson (Franklin Lakes, NJ). Alexa Fluor 568-phalloidin and Alexa Fluor 488-cholera toxin subunit B (CTxB) were purchased from Invitrogen. An inhibitor of cyclic adenosine monophosphate (cAMP), Rp-cAMPS, and an analogue of cGMP, 8-bromo-cGMP, were purchase from Calbiochem (Darmstadt, Germany).
Deadhesion assay. A431 cells were plated at a subconfluent concentration in a 96-well plate and cultured overnight. Next, 1 pmol/mL of recombinant protein with an AP tag and/or chemically synthesized peptide was added, and the plate was shaken for 30 minutes at 1,200 rpm on an OPM-103 microplate mixer (As One Corporation, Osaka, Japan). Detached cells were aspirated with a pipette and counted using a hemocytometer. Recombinant activation peptide was used as a negative control. The number of detached cells in the negative control experiment was arbitrarily set to 1. Results are expressed as the mean 6 standard deviation (SD).
Immunohistochemistry. Cells were plated on fibronectin-coated dishes. To examine the functions of peptide 193-216, cells were treated with 1 pmol/mL of chemically synthesized peptide 193-216 for 10 minutes. When staining with CTxB was necessary, Alexa Fluor 488-CTxB was added to the medium 5 minutes before fixation. Cells were fixed in PBS with 4% paraformaldehyde, permeabilized in PBS with 0.1% Triton X-100, and incubated with primary antibodies, followed by detection with Alexa Fluor 488-or Alexa Fluor 568-conjugated antirat, mouse, or rabbit IgG (Invitrogen). When necessary, cells were then stained with Alexa Fluor 568-phalloidin to detect actin and Hoechst33342 to detect nuclei. Cells were examined using an Axioskop 2 fluorescence microscope (Carl Zeiss, Oberkochen, Germany) or a TCS-SP5 confocal microscope (Leica, Wetzlar, Germany). Images acquired using the Axioskop 2plus microscope at 100 3 final magnification were analyzed using the Axiovision software package (Carl Zeiss).
Cell shape analysis. Cells were plated subconfluently; at 24 hours after plating, cells were treated with 1 pmol/ mL of peptide 193-216 for 30 minutes. Rp-cAMPS or 8bromo-cGMP was added to the medium 30 minutes before fixation at various concentrations. The cells were then fixed in PBS with 4% paraformaldehyde, permeabilized in PBS with 0.1% Triton X-100 and incubated with Alexa Fluor 568-phalloidin to detect actin and Hoechst33342 to detect nuclei. Cells were photographed under fluorescence microscopy. The area of the dish covered with cells and number of nuclei were determined using Popimaging software (Digitalbeeing kid, Kanagawa, Japan). To evaluate the thickness of lamellipodium-like protrusions, photographs were acquired every micrometer using a TCS-SP5 confocal microscope (Leica).
Electron microscopy. Cells were cultured on fibronectin-coated cover-glasses for 16 hours and then treated with 1 pmol/mL of peptide 193-216 for 30 minutes. Cells were then fixed in 4% paraformaldehyde followed by 2.5% glutaraldehyde in cacodylate buffer (pH 7.4), treated with 1% cacodylate-buffered (0.1 M) OsO4, embedded in 1% Epon812, and sectioned. Finally, ultra-thin sections were stained with saturated uranyl acetate and lead citrate and examined by electron microscopy.
Western blotting. HUVECs were cultured for 24 hours in a 24-well dish and treated with 1 pmol/mL of chemically synthesized activation peptide 193-216 for various durations. Samples were harvested with 100 mL of sample buffer. Proteins in a sample (1/4) were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis and transferred to a polyvinylidene fluoride membrane (ATTO, Tokyo, Japan). The membrane was incubated with anti-eNOS antibody (Abcam, Cambridge, UK) followed by a horseradish peroxidase-conjugated secondary antibody, and immunoreactive proteins were detected using Western blot Ultra-sensitive HRP substrate (Takara). Chemiluminescence was detected using LumiCube (Liponix, Tokyo, Japan) and analyzed using JustTLC software (Sweday, Lund, Sweden).
In vitro permeability assay. Experiments were conducted using an In vitro Vascular Permeability Assay kit (Chemicon, Billerica, Mass) according to the manufacturer's protocol. Briefly, HUVECs were plated confluently in the upper chambers and cultured with 100 ng/mL of IL-1b for 24 hours. The cells were then cultured with various concentrations of chemically synthesized peptide 193-216 or control peptide for 60 minutes. Fluorescein isothiocyanate-conjugated dextran was added to the upper chambers, and after 5 minutes, the medium from the lower chambers was harvested. Florescence intensity was measured using a microplate reader. The experiment was repeated 3 times. Results are expressed as the mean 6 SD.
Measurement of cGMP. Experiments were performed using a cGMP Direct Immunoassay kit (Abcam). Briefly, HUVECs were plated confluently in a 24-well dish. The cells were then cultured with 10 pmol/mL of chemically synthesized peptide 193-216 or control peptide for various durations. Cell lysates were prepared, and the amount of cGMP in the lysates was determined according to the manufacturer's protocol.
The experiment was repeated 3 times. Results are expressed as the mean 6 SD.
Mouse sepsis model. Animal experiments described in this study were carried out in accordance with both institutional and National Institutes of Health animal care regulations. This study was approved by the animal study committee of Nihon University (AP13M025). Five-week-old male mice were purchased from CLEA Japan (Tokyo, Japan). Mice were injected with LPS (Wako, Tokyo, Japan) intravenously in the tail vein at a dose of 100-mg/g body weight. After 3 hours, mice were then injected intravenously in the tail vein with chemically synthesized peptide 193-216 or control peptide at 350-ng/g body weight, and 1 hour later, mice were sacrificed by cervical dislocation and the lungs immediately harvested. After the lungs were weighed, 5-mm-thick frozen sections were prepared and stained with hematoxylin and eosin.
Statistical analysis. Results are expressed as the mean 6 SD. The significance of differences was evaluated using Wilcoxon's rank sum test. Statistical significance was defined as P , 0.05.
RESULTS
Determination of the amino acid sequence essential for the activity of the activation peptide of FIX. Kitano et al. 24 established a deadhesion assay in which the functions of the first EGF domain and the activation peptide of FIX could be clearly quantified using A431 cells. Their assay was used in the present study to determine the FIX activation peptide amino acid sequence essential for its activity (Supplemental Fig 1A) . To characterize the activity of the activation peptide, the effect of the first EGF domain of FIX on cell adhesion was examined. The first EGF domain of FIX-attenuated cell adhesion to matrix, whereas full-length FIX (amino acids 47-471) and a recombinant activation peptide 193-236 suppressed this attenuation. Because amino acid sequences of mammalian activation peptides exhibit a high degree of homology at the Nterminus, N-terminal peptides were chemically synthesized (Supplemental Fig 1B) . Chemically synthesized peptide 193-216 also suppressed the activity of the first EGF domain of FIX, but chemically synthesized peptide 193-210 did not. Chemically synthesized peptide 193-216 tended to be less effective than peptide 193-236. However, from clinical application perspective, short, chemically synthesized peptides typically present a cost advantage. For further study, we therefore used peptide 193-216.
Morphological changes induced by the activation peptide of FIX. HUVECs were used to examine the effect of the activation peptide on cell morphology. Fig 1A shows morphological changes in HUVECs over time in the presence of peptide 193-216. Three minutes after administration of the peptide, stress fibers disappeared, and the intensity of fluorescence from polymerized actin declined significantly ( Fig 1A, B) . Another morphological change induced by peptide 193-216 was the formation of small lamellipodiumlike protrusions with actin bundles at their edges. Some control cells exhibited similar lamellipodia, as shown Fig 1A. The protrusions in the presence of the peptide and those in control cells differed with respect to thickness at the edge, as measured using confocal microscopy. Most of the lamellipodia in control cells were thicker than 5 mm, whereas most of the lamellipodium-like protrusions in peptide-treated cells were less thick than 5-mm thick ( Fig 1C) . The extension of these protrusions in multiple directions appeared to indicate spreading rather than migration. Finally, 30 minutes after the administration of the peptide, the cell-covered area increased by 16% ( Fig 1D) . These data indicate that the FIX activation peptide induces spreading in HUVECs.
Squamous cell carcinoma-derived A431 cells were also used to examine the cell specificity of the morphological phenotype induced by the activation peptide.
Control A431 cells adhered at several pointy protrusions, with intensive actin staining corresponding to focal adhesions (Supplemental Fig 2A) . By 30 minutes after the administration of peptide 193-216, treated cells assumed a square shape, with a few broad protrusions exhibiting actin staining along the edges. The recombinant activation peptide increased the average cell adhesion area by 1.3 times compared with control cells (Supplemental Fig 2B) . The activity of the activation peptide with regard to cell spreading is thus not endothelial cell specific.
To evaluate the effect of the activation peptide on intercellular adhesion, subconfluently cultured HU-VECs were used. The time course of intercellular adhesion of cells treated with peptide 193-216 was examined using immunohistochemistry with an anti-VE-cadherin antibody and phalloidin (Fig 2A) . The distribution of VE-cadherin became fuzzy in appearance 30 minutes after treatment with peptide 193-216 (Fig 2A, B) . The fuzzy intercellular adhesion was due to filopodia formed between cells. The appearance of areas of intercellular adhesion became more linear and sharper after 60 minutes.
Another morphological change induced by peptide 193-216 was the appearance of widely spread protrusions that had a lamellipodium-like appearance (Fig 2A, C) . To analyze these protrusions, HUVECs were observed using confocal microscopy (Fig 2D) . At the level of 1.5 mm from the cover glass, VEcadherin was stained lineally and colocalized with polymerized actin, indicating that adherens junctions involving VE-cadherin and actin were formed at this level. At lower levels, VE-cadherin staining exhibited a more ''lacy'' appearance, and the intercellular adhesion interface as indicated by VE-cadherin extended diagonally. Polymerized actin did not colocalize with VE-cadherin at the lower levels. These results indicated that adjacent cells overlapped at their interface and that the architecture of cell adhesion was distinct from that of a typical adherens junction.
It has been reported that intercellular adhesion between A431 cells is enhanced by the activation peptide. To investigate whether the lamellipodium-like protrusions induced in endothelial cells by treatment with peptide 193-216 are endothelial cell specific, A431 cells were stained with antibodies against E-cadherin and b-catenin ( Supplemental Fig 3) . Treatment with peptide 193-216 caused the areas of intercellular adhesion to become more straight and continuous, but treatment did not induce the formation of lamellipodium-like protrusions as seen in HUVECs.
The endothelial cell-specific formation of lamellipodium-like protrusions by treatment with peptide 193-216 and their shape (Fig 2) reminded us of the lateral border recycling compartment, an endothelial cell-specific structure at sites of intercellular adhesion. HUVECs were therefore stained with an antibody specific for platelet endothelial cell adhesion molecule (PECAM; a marker of LBRCs; Fig 3A) and an anti-bcatenin antibody. In control cells, areas of intercellular adhesion were stained with the anti-b-catenin antibody; however, some areas of intercellular adhesion were not stained with the anti-PECAM antibody. In contrast, in HUVECs treated with peptide 193-216, b-catenin, and PECAM were colocalized at sites of intercellular adhesion. Digital magnification revealed that colocalization of b-catenin and PECAM was not homogeneous in control cells. The expression of b-catenin was linear, indicating the presence of adherens junctions. However, PECAM was not intensively expressed at adherens junctions and was distributed widely ( Fig 3B) . In pep-tide 193-216-treated cells, a lace-like pattern of b-catenin and PECAM colocalization was observed. Colocalization of b-catenin and PECAM was subsequently analyzed by confocal microscopy. Vertical cross-sectional views of HUVECs stained with antibodies against b-catenin and PECAM are shown in Fig 3C. In control cells, b-catenin was detected at higher levels than PECAM, consistent with the location of LBRCs along the basal side of adherens junctions. In contrast, b-catenin and PECAM were colocalized at the sites of intercellular adhesion in the presence of peptide 193-216. To confirm that b-catenin was localized in adherens junctions, cells were stained with antibodies against VE-cadherin and b-catenin, both of which were found to be colocalized in control cells and cells treated with peptide 193-216 ( Fig 3D) .
For further study of intercellular adhesion in vitro, scanning electron microscopy was used. In control cells cultured for 16 hours, simple, short overlapping areas of intercellular adhesion were observed ( Fig 3E) . In peptide 193-216-treated cells, some areas of intercellular adhesion exhibited an intricate configuration.
Our results suggest that cell spreading induced by peptide 193-216 (Fig 1) effectively closes small gaps between cells. In addition, the enhanced and intricate configuration of intercellular adhesion induced by peptide 193-216 (Figs 2 and 3 ) could increase the integrity of the endothelial cell monolayer, thus decreasing its permeability. To examine the effect of peptide 193-216 on intercellular gaps, the number of gaps between HUVECs was determined using fluorescence microscopy ( Fig 4A) . Observation of HUVECs stained with phalloidin and Hoechst33342 revealed small gaps of several micrometers in diameter between cells, in addition to small lamellipodium-like protrusions several micrometers in width with actin bundles at their edges along the intercellular interface. Treatment with peptide 193-216 enlarged the protrusions along the intercellular interface to tens of micrometers in width. The number of gaps decreased by 66% in cells treated with peptide 193-216 ( Fig 4B) . The observed deformation of the protrusions suggests that peptide 193-216 changes the configuration of the intercellular interface to close intercellular gaps. activation peptide on endothelial cell barrier function, immunohistochemistry and in vitro cell permeability assays were used. HUVECs were cultured in the presence of IL-1b for 24 hours, and then the cells were incubated with 10 pmol/mL of peptide 193-216 for 30 minutes. IL-1b inhibited intercellular adhesion, as evidenced by staining with anti-VE-cadherin antibody and phalloidin, whereas peptide 193-216 suppressed this effect of IL-1b ( Fig 4C) . In an in vitro model of permeability, monolayers of endothelial cells were cultured in the presence of IL-1b for 24 hours. The cells were then incubated with various concentrations of the synthesized peptide. Permeability was evaluated by monitoring the passage of fluorescein isothiocyanatedextran through the cell monolayer ( Fig 4D) .
Treatment with IL-1b increased monolayer permeability 6.5-fold. Peptide 193-216 suppressed the IL-1b-induced increase in permeability dose dependently, with suppression almost to the control level observed with 10 pmol/mL of peptide 193-216.
We hypothesized that the activation peptide induces the closure of small gaps between epithelial and endothelial cell sheets via cell spreading. To investigate whether the activation peptide promotes the healing of small wounds in epithelial cell monolayers, the healing process of a linear wound the width of a single cell made using a razor blade was observed ( Supplemental Fig 4) . In control experiments, cells migrated into the wound within 30 minutes of injury. As a result of cell migration, new gaps were formed behind the migrating cells. 
=
In contrast, treatment with the activation peptide resulted in closure of the wound without the formation of new gaps. These results suggest that the activation peptide induces the closure of small gaps in epithelial and endothelial cell sheets via promoting cell spreading.
Signaling mediated by the activation peptide of FIX. The mechanisms of the activation peptide's effects were also investigated. Nitric oxide is known to mediate hyper-permeability induced by humoral factors such as VEGF and bradykinin. Western blotting ( Fig 5A) indicated a decrease in the level of eNOS expression in HUVECs 30 minutes after administration of peptide 193-216. Because cells responded to peptide 193-216 within several minutes (Fig 1A) , the response shown in Fig 5A is too slow. Thus, another mechanism must explain the rapid response to peptide 193-216. The intracellular distribution of eNOS was therefore investigated. The distribution of eNOS was examined by immunocytochemical analysis at 10 minutes after peptide treatment ( Fig 5B) using caveolin-1, a marker of caveolae. Control cells exhibited some clusters of caveolae at the cell edges, particularly at protrusions. Treatment with the activation peptide caused the cells to assume a spheroidal shape, with smooth edges, with a 40% decrease in the number of eNOS-containing clusters of caveolae ( Fig 5C) . Colocalization of eNOS and CTxB, a marker of lipid rafts, was also examined (Supplemental Fig 5) . CTxB colocalized with eNOS at cell edges, as caveolin-1 did. Both eNOS and CTxB disappeared from the membrane after treatment with peptide 193-216. Because the decrease in eNOS expression and change in the distribution of eNOS protein suggested that peptide 193-216 suppresses eNOS function, the amount of intracellular cGMP was examined ( Fig 5D) . Peptide 193-216 treatment significantly decreased the level of cGMP within 10 minutes. To investigate whether peptide 193-216 signaling is cGMP dependent, the effect of 8-bromo cGMP was examined. Administration of 8-bromo cGMP resulted in a dose-dependent suppression of cell spreading induced by peptide 193-216 ( Fig 5E) .
Finally, the amount of intracellular cAMP was determined, because the phenotype induced by treatment with the activation peptide seemed to be similar to that associated with an increase in cAMP. Treatment with peptide 193-216 resulted in a slight decrease in the intracellular cAMP level, rather than an increase (Supplemental Fig 6A) . To confirm that the signaling pathway for spreading by cAMP was functioning in our experimental system, the effects of a cAMP inhibitor were examined (Supplemental Fig 6B, C) . Rp-cAMPS suppressed the increase in cell adhesion area and decrease in polymerized actin induced by peptide 193-216.
Therapeutic effects of the activation peptide in a mouse model of sepsis. Because the activation peptide was shown to regulate eNOS expression and function and suppress the permeability of the endothelial cell monolayer in an in vitro sepsis model ( Fig 5D) , it was expected to demonstrate similar effects in an in vivo sepsis model. First, normal mice were injected intravenously with peptide 193-216 to examine the safety of the peptide. No harmful effects associated with the injection were noted on macroscopic observation or by the wet lung/body weight ratio 1 hour after the injection (Fig 6A) . Next, model mice were generated by intravenous injection of LPS. Peptide 193-216 was injected intravenously 3 hours after LPS injection, and the lungs were harvested 60 minutes after peptide 193-216 administration. The wet lung/body weight ratio significantly increased in model mice, by 28%, but the injection of peptide 193-216 significantly suppressed this increase. Hematoxylin and eosin staining revealed that the lung specimens from septic model mice had a thicker interstitium, with cell infiltration, which was improved by peptide 193-216 treatment (Fig 6B) .
DISCUSSION
This study showed that the activation peptide of FIX induces cell spreading. Treatment with chemically synthesized activation peptide decreased actin polymerization within 3 minutes, induced the formation of multidirectional thin and wide protrusions, and increased the cell adhesion area. Peptide treatment also changed the architecture of intercellular adhesion sites. The shape of the cell interface became more complex, and the distribution of adhesion molecules such as VE-cadherin, b-catenin, and PECAM changed. These effects of the activation peptide resulted in an increase in the barrier function of endothelial cell monolayers in vitro and regulated vascular permeability in vivo.
The signaling for cell spreading induced by the activation peptide involved a decrease in cGMP with eNOS suppression. Treatment with the activation peptide decreased the expression of eNOS protein and altered its subcellular distribution. Intracellular cGMP levels decreased rapidly after the administration of activation peptide. Addition of 8-bromo-cGMP abolished the effect of the activation peptide on cell morphology, indicating that a decrease in the level of cGMP is essential for activation peptide signaling. The role of the NO-cGMP pathway in endothelial barrier function is controversial. Some reports indicate that cGMP protects the barrier function, [27] [28] [29] but others do not. 11, [30] [31] [32] Surapisitchat and Beavo 33 reviewed the relevant literature and reported that cGMP suppresses endothelial permeability under physiological conditions and suppresses the barrier function under inflammatory conditions. They proposed that cGMP activates PDE2, which degrades cAMP under inflammatory conditions. A decrease in cGMP could increase intracellular cAMP levels, stimulating cell spreading, and preserving the endothelial barrier function. [34] [35] [36] [37] In this study, treatment with the activation peptide resulted in a decrease rather than an increase in the intracellular cAMP level. These results suggest that there are cAMP-independent pathways in which a decrease in cGMP level leads to cell spreading.
The suppression of caveolae clustering could be involved in regulation of eNOS by the activation peptide. In the present study, intracellular cGMP started to decrease within 10 minutes after the treatment with the activation peptide, and disappearance of eNOS from the cell membrane was observed after 10 minutes, with the loss of caveolae clusters. It has been reported that eNOS is a caveolae protein and that internalization of eNOS is essential for its endothelial permeabilityincreasing activity. 38, 39 The inhibition of caveolae clustering may play a negative role in NO generation by inhibiting eNOS internalization. Sinha et al. 40 reported that the impairment of caveolae formation generates additional cell membrane in cells swollen under hypotonic stress. Increased cell membrane area may contribute to cell spreading induced by the activation peptide. 41 Cell spreading induced by the activation peptide is an isotropic process involving multidirectional protrusions and differs from spreading involving unidirectional lamellipodia for migration. Some studies have shown that isotropic cell spreading in the early stage of cell adhesion is a hydrodynamic process. 42 The dynamics of adhesion follow a universal power-law behavior and are independent of the adhesion surface and the distribution of adhesion receptors. The process is largely controlled by the membrane surface load and membrane bending rigidity, which in turn is controlled by disruption of polymerized actin. 43, 44 In the present study, treatment with activation peptide quickly reduced actin polymerization and induced isotropic spreading. The dismantling of the actin cytoskeleton could be involved in cell spreading mediated by the activation peptide.
Cell spreading appears to play an important role in gap closure induced by the activation peptide. 45, 46 Many studies involving gap closure for the maintenance of epithelial barrier functions have been reported. [47] [48] [49] [50] Three mechanisms have been proposed. The first mechanism involves gap closure by cell migration with lamellipodium protrusions, controlled by Rac1 GTPase. 51, 46 The second mechanism involves purse-string closure by assembly and contraction of a multicellular actomyosin belt lining the gap. 52, 53 This process is controlled by RhoA, ROCK, and myosin light-chain kinase. Anon et al. 51 discussed a third mechanism for closure of gaps smaller than 20 mm. This mechanism is independent of Rac1, ROCK, or myosin light-chain kinase and could be based on cell spreading. Treatment with peptide 193-216 induces the formation of lamellipodial protrusions, suggesting that the first mechanism based on cell migration with lamellipodial protrusions could be the mechanism through which peptide 193-216 acts. However, our experimental results eliminate this mechanism. Cells formed multidirectional protrusions in the presence of peptide 193-216 in the present study ( Fig 1A) . Generally, lamellipodia used for migration are unidirectional. In addition, Kitano et al. reported that the activation peptide of FIX suppresses cell migration. Because treatment with peptide 193-216 suppressed the formation of new gaps behind migrating cells in the present study ( Supplemental Fig 4) , gap closure based on cell spreading appears to be a likely mechanism of the activation peptide.
The distribution of PECAM plays roles in the remodeling of intercellular adhesion and the enhancement of endothelial barrier function. [54] [55] [56] [57] Endothelial permeability is regulated by 2 pathways, paracellular, and transcellular. The paracellular pathway is regulated by endothelial barrier-related genes, such as those encoding adherens junction and tight junction proteins. The activation peptide rearranged adherens junction proteins and enhanced endothelial barrier function. In addition, the activation peptide rearranged PECAM at sites of intercellular adhesion. It has been reported that PECAM is not an adherens junction protein and is localized in LBRCs. 58, 59 However, PECAM is essential for the formation of adherens junctions. The colocalization of PECAM and adherens junction components may be indicative of remodeling of intercellular adhesion sites through their interaction. PECAM is essential for leukocyte diapedesis in LBRCs. [60] [61] [62] How leukocytes can migrate between endothelial cells and avoid deleterious permeability changes remains an important question. Interactions between PECAM and adherens junction proteins may play critical roles in maintaining the integrity of intercellular adhesion sites and the regulation of endothelial cell layer permeability.
Possible physiological roles of the activation peptide should also be discussed. Kitano et al. reported that active FIX and recombinant proteins containing the first EGF domain of FIX attenuate intercellular adhesion and increase cell migration. In contrast, the inactive circulatory form of FIX and activation peptide act in an opposing manner. In the present study, the activation peptide opposed the action of the first EGF domain of FIX ( Supplemental Fig 1) . These data indicate the possibility that the balance between active and inactive FIX plays a significant role in the physiological function of FIX. The functions of active FIX along with decreased intercellular adhesion and increased cell migration are reminiscent of VEGF-stimulated angiogenesis in wound healing. 63, 64 However, it would seem unlikely that suppression of angiogenesis by inactive FIX or cleaved activation peptide is beneficial in wound healing. A hypothesis to explain the function of inactive FIX and activation peptide is that they function in healthy tissues as opposed to wounds. Inactive FIX could prevent healthy vessels from endothelial hyper-permeability induced by active FIX from injured tissue. In tissues in which blood flow is preserved, inactive FIX supplied via the blood could predominate over active FIX, contributing to the maintenance of endothelial barrier function. In contrast, in tissues in which the blood flow is impeded by injury or coagulation, active FIX could predominate but not spread to healthy tissues due to the interruption of blood flow. To prove this hypothesis, further study will be necessary.
The activation peptide is a potential agent for use in treating diseases in which vascular permeability is increased. Intravenous injection with activation peptide improves lung edema generated by endotoxin. This animal disease model is considered to represent not only sepsis but also systemic inflammatory response syndrome (SIRS), a condition involving systemic inflammation, organ dysfunction, and organ failure. 65, 66 No therapeutic methods for treating SIRS are currently available. Barrier-protective endogenous molecules such as thrombomodulin, S1P, and APC have been proposed as agents for treating SIRS. Thrombomodulin functions via cAMP. 20 S1P and APC increase NO production, and APC signaling is coordinately activated with S1P. 67, 68 Our data indicate that the activation peptide functions via a different signaling pathway from those molecules. The activation peptide mechanism is cAMP independent and requires a decrease in cGMP. The activation peptide could thus be used in a supplemental manner in the treatment of pathologic conditions that are resistant to the abovementioned agents. With an eye toward clinical applications, the biological characteristics of the peptide, including its circulating half-life, fate, and immunogenicity, should be investigated. 
